Keryx Biopharmaceuticals, Inc. (KERX) Tops Q2 EPS by 1c

Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) reported Q2 EPS of ($0.24), $0.01 better than the analyst estimate of ($0.25).

At June 30, 2014, the Company had cash, cash equivalents, interest receivable, and investment securities of $137.1 million, as compared to $55.7 million at December 31, 2013.

"The transformation that our company has undergone since the beginning of the year is remarkable," said Ron Bentsur, Chief Executive Officer of Keryx. "As we prepare to complete the transition to a commercial-stage company, we have added a wealth of talent to the organization, most recently with the hiring of our regional sales directors. We remain focused on launch preparations in order to best position Zerenex for commercial success, pending potential drug approval."

For earnings history and earnings-related data on Keryx Biopharmaceuticals, Inc. (KERX) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Instil Bio Inc. (TIL) Misses Q2 EPS by 21c
• Barclays: US stocks sell off despite historic earnings beats